Sobre construir imunidade contra o capitalismo tardio que consome o planeta e os nossos corpos.

60 Degrees Pharmaceuticals (NASDAQ: SXTP) submitted a New Dietary Ingredient Notification (NDIN) to the FDA on March 11, 2026, for an Australian Chestnut Extract product; FDA review runs through May 25, 2026.The company also signed an option to license Florida State University capsule formulation methods and previously exercised a January 2026 license option for large-scale purification rights for castanospermine.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported FY2025 results on March 31, 2026, with net product revenues up 65% to $1.005 million and gross profit of ~$223.8k. Operating expenses fell to ~$8.4 million, and net loss improved to ~$7.37 million. The company raised ~$4.03 million via its ATM, exhausting current shelf capacity.Clinical and commercial progress included expanded access cures for relapsing babesiosis, pharmacy partnerships with GoodRx and Runway Health, a Phase 2 site opening, and a Yale tafenoquine license.

60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported that all three patients in its expanded‑use trial of tafenoquine for relapsing babesiosis in immunosuppressed patients achieved cure after completing the regimen.The open‑label study used weekly tafenoquine added to atovaquone‑containing combinations sustained until two consecutive negative PCRs; combined data with a 2024 Yale report suggest near 100% cure in seven patients. Tafenoquine is not FDA‑approved for babesiosis and is approved in the U.S. for malaria prophylaxis as ARAKODA.

Partnership adds a travel-focused consumer telehealth platform to the ARAKODA ® marketing strategy, offering a new convenience to people planning travel to malaria-endemic regions of the world ARAKODA is the only FDA-approved, broad spectrum, once-weekly malaria prevention option for international

60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it will effect a one-for-four (1:4) reverse stock

60 Degrees Pharmaceuticals (NASDAQ: SXTP) announced a planned expansion of sales and marketing for ARAKODA after a 6-month commercial pilot showed increasing product sales among prescribers. Plans for 2026 include doubling inside sales representatives, a new GoodRx partnership to broaden point-of-sale visibility, and an enhanced digital "surround sound" marketing campaign to boost prescriber awareness and engagement.Separately, the company will add at least two babesiosis clinical sites for ongoing randomized and expanded-access studies following FDA feedback on its Breakthrough Therapy designation request; FDA declined the request but acknowledged babesiosis as serious and suggested resubmission with controlled-trial data. Tafenoquine (ARAKODA) remains approved for malaria prophylaxis and is not approved for babesiosis treatment.

90-day trial will measure change in general fatigue in patients with chronic babesiosis following tafenoquine treatment Study will run approximately 12 months and enroll up to 100 patients Internal estimates of the unmet medical need are between 4,400 and 190,000 cases annually, with no existing

60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on

60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported that the first patient completing its expanded access study of ARAKODA® (tafenoquine) for relapsing babesiosis tested negative for Babesia by both a Mayo Clinic RT-PCR and an FDA-licensed RNA amplification assay that is described as at least 100x more sensitive than standard RT-PCR.On October 3, 2025 the company submitted a Breakthrough Therapy request to FDA and plans a Type B meeting in early 2026 to discuss requirements for a supplementary NDA; remaining patients are expected to finish between January and October 2026 and clinical data are expected in second half of 2026.

Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competition A $5K donation from the Company was split between ILADEF and GLA to recognize the winning name B-FREE, a Phase 2 trial, will commence in early November and run for approximately 12 months

60 Degrees Pharmaceuticals (NASDAQ: SXTP) CEO Dr. Geoff Dow to present at H.C. Wainwright Global Investment Conference on Sept 9, 3:30 PM ET. One-on-one meetings available.